Exelixis, Inc.

Stocks

Market Closed - Nasdaq 16:00:00 2026-09-04 EDT			5-day change	1st Jan Change
59.01 ^USD	-0.20%		+8.00%	+34.63%

08-31	Exelixis Wins Appeal in Patent Case Against MSN Laboratories	MT
08-05	Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026

Published on 12/10/2025 at 04:20 pm EST - Modified on 12/11/2025 at 06:07 am EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Welcome to the Exelixis virtual event. Please welcome Executive Vice President of Public Affairs and Investor Relations, Susan Hubbard.

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

08-31	Exelixis Wins Appeal in Patent Case Against MSN Laboratories	MT
08-05	Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026
08-05	(EXEL) Exelixis Now Expects Fiscal 2026 Revenue Range $2.50B-$2.55B, vs. FactSet Est of $2.60B	MT
08-05	Earnings Flash (EXEL) Exelixis, Inc. Reports Q2 Revenue $628.7M, vs. FactSet Est of $636.4M	MT
08-05	Earnings Flash (EXEL) Exelixis Posts Q2 Revenue $628.7M, vs. FactSet Est of $636.4M	MT
08-05	Exelixis Q2 Adjusted Earnings, Revenue Rise; Shares Drop After Hours	MT
08-05	Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on May 5, 2026.	CI
08-05	Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on November 4, 2025.	CI
08-05	Exelixis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-05	Earnings Flash (EXEL) Exelixis, Inc. Posts Q2 Adjusted EPS $0.91 per Share, vs. FactSet Est of $0.85	MT
08-05	Exelixis, Inc. Updates Earnings Guidance for Fiscal Year 2026	CI
07-23	Analyst recommendations: Duke Energy, JPMorgan Chase, M&T Bank, Super Micro, Texas Instruments…
07-13	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…
07-07	RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating	MT
07-02	Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says	MT